Does amikacin treatment cause subclinical hearing loss in patients with cystic fibrosis?

Solmaz F., Gundogdu E., AKDUMAN D., Haksever M., Dikici O., Unal F.

TOXICOLOGY REPORTS, vol.3, pp.401-404, 2016 (ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 3
  • Publication Date: 2016
  • Doi Number: 10.1016/j.toxrep.2016.03.010
  • Journal Name: TOXICOLOGY REPORTS
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus
  • Page Numbers: pp.401-404
  • Bursa Uludag University Affiliated: No

Abstract

Introduction: Aminoglycosides (AGs) have been widely used for potential life-threatening bacterial infections. Although AGs are well known for their ototoxic side effects, some AGs such as amikacin are considered less harmful to auditory functions; thus, auditory monitoring is mostly neglected during treatment with these drugs.